Drug Trial Radar · NCT07219368
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Oct 8, 2025
Primary completion
Oct 20, 2026
Study completion Oct 20, 2026
Sponsor
- Lead sponsor
- Mirador Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.
Conditions
- Healthy Volunteer
Interventions
MT-201Drug
MT-201
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with non-SAEs and SAESTime frame: Up to 40 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mirador Clinical Department, San Diego, California 92121
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.